How many private cannabis prescriptions have been applied for

The request was successful.

Dear Medicines and Healthcare products Regulatory Agency,

How many licenses for a specials medicine importation has been applied for since November 2018 when specialist consultants became able to legally prescribe?

Yours faithfully,

Greg de Hoedt
UK Cannabis Social Clubs

MHRA Customer Services, Medicines and Healthcare Products Regulatory Agency

Dear Enquirer,
 
Thank you for your enquiry to the Medicines and Healthcare products
Regulatory Agency. This automated response confirms that we have received
your email and that it will be dealt with as quickly as possible.
 
You can expect a reply from us within a few days for a straightforward
request, however where a more detailed response or contribution from a
specialist is required this is likely to take longer.  We endeavour to
respond to requests within the Department of Health’s target response time
of 18 working days; or 20 working days if your request is a Freedom of
Information request; one month if you are making a request for access to
your personal data under the General Data Protection Regulation 2018.
 
Our website contains a wealth of information which may assist with your
enquiry. Some of our popular pages are:
 
Clinical trials of medicines and Clinical investigation for a medical
device:

[1]https://www.gov.uk/medicines-medical-dev...
       
Manufacturer’s and wholesale dealer’s licences:

[2]https://www.gov.uk/apply-for-manufacture...
 
Registration of medical devices, opticians and dental laboratories:

[3]https://www.gov.uk/register-as-a-manufac...
 
Reporting a problem with a medicine or medical device:

[4]https://www.gov.uk/report-problem-medici...
 
Deciding if your product is a medicine or a medical device:

[5]https://www.gov.uk/decide-if-your-produc...
 
Reporting a counterfeit medical product:
 
[6]https://yellowcard.mhra.gov.uk/counterfe...
 
We are continuously looking to make improvements to the service offered by
our Customer Services team, so if you have any feedback please don’t
hesitate to get in touch with us either on the number below or by
completing the form at the link below:
[7]https://www.surveymonkey.com/s/MHRACusto...
 
If you have not heard from us after 18 working days then please contact us
on 020 3080 6000.
 
Kind regards
 
The Customer Services Team
Communications division
 
Medicines and Healthcare products Regulatory Agency
10 South Colonnade, Canary Wharf, London E14 4PU
Telephone: 020 3080 6000
Email: [8][MHRA request email]
Stay connected: [9]mhra.gov.uk/stayconnected
 
The Agency will be closed on Monday, 27 and Tuesday, 28 May 2019. We will
re-open on Wednesday, 29 May 2019.
 
All emails are retained by the Agency in a secure area together with the
Agency’s response, for eight years in accordance with our Retention and
Disposal Schedule. Our privacy notice can be found [10]here.
 
Please note this is an automated reply; please do not respond to this
message.
 
 

show quoted sections

MHRA Customer Services, Medicines and Healthcare Products Regulatory Agency

Dear Greg de Hoedt,

 

Thank you for your email of 17 June where you have asked “How many
licenses for a specials medicine importation has been applied for since
November 2018 when specialist consultants became able to legally
prescribe?”

 

The Home Office is responsible for licences for import of Schedule 2
cannabinoids, however the MHRA also has to be notified for import of
unlicensed medicines by holders of relevant Wholesale Dealer's
Authorisations (WDA(H)) or Manufacturer's "Specials" Licences (MS) under
the Human Medicines Regulation SI 2012/1916.

 

From [1]The supply, manufacture, importation and distribution of
unlicensed cannabis based products for medicinal use in humans ‘specials’:

 

Classification and scheduling of cannabis

Cannabis, cannabis resin, cannabinol and cannabinol derivatives are
classified as a Class B drugs under the Misuse of Drugs Act 1971, based on
a harms assessment. This classification dictates the penalties for
committing offences with the drug such as possession and intent to supply
and is used to prioritise the law enforcement response. The classification
of the drug is entirely separate from its scheduling.

 

The Misuse of Drugs Regulations 2001 (‘the 2001 Regulations’) provides the
legal framework for access to controlled drugs for legitimate purposes.
Cannabis (the plant material, excluding the stalks and seeds), cannabis
resin, cannabinol and cannabinol derivatives are listed under Schedule 1
of the 2001 Regulations. These definitions cover, amongst other chemical
constituents, the cannabinoid THC2. THC is the principal psychoactive
constituent of cannabis.

By law, the cultivation, production, supply and possession of cannabis
under Schedule 1 is only permitted under a Home Office licence. For more
information on Home Office Licensing, see
[2]https://www.gov.uk/guidance/controlled-d....

 

With effect from the 1 November 2018, Cannabis Based Medicinal Products
for Use in Humans (“CBPMs”) will be listed in Schedule 2 to the 2001
Regulations. Only forms of cannabis – and the associated controlled
products – which meet this definition will fall into Schedule 2.

 

The total number of notifications received by the MHRA for Schedule 2
cannabinoids since 01 Nov 2018 is 87 as at 14-Jun-2019.

 

Kind Regards

 

Customer Services

Communications division

Medicines and Healthcare Products Regulatory Agency

10 South Colonnade, Canary Wharf, London E14 4PU

Telephone: 020 3080 6000

Email: [3][MHRA request email]

Stay connected

 

 

show quoted sections